

Title (en)
NOVEL COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF BREATHING CONTROL DISORDERS OR DISEASES

Title (de)
NEUARTIGE VERBINDUNGEN UND ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON ATEMKONTROLLSTÖRUNGEN ODER - ERKRANKUNGEN

Title (fr)
NOUVEAUX COMPOSÉS ET NOUVELLES COMPOSITIONS POUR LE TRAITEMENT DE TROUBLES OU DE MALADIES DU CONTRÔLE DE LA RESPIRATION

Publication
EP 2855438 A4 20160224 (EN)

Application
EP 13798039 A 20130529

Priority

- US 201213482837 A 20120529
- US 2013043052 W 20130529

Abstract (en)
[origin: WO2013181217A2] The present invention includes compositions that are useful in the treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a pharmaceutical formulation of the invention.

IPC 8 full level
C07D 251/54 (2006.01); **A61K 31/53** (2006.01); **A61K 45/06** (2006.01); **A61P 11/00** (2006.01)

CPC (source: EP KR)
A61K 31/433 (2013.01 - EP); **A61K 31/505** (2013.01 - EP KR); **A61K 31/519** (2013.01 - EP); **A61K 31/522** (2013.01 - EP KR); **A61K 31/53** (2013.01 - EP KR); **A61K 31/5355** (2013.01 - EP); **A61K 31/57** (2013.01 - EP); **A61K 45/06** (2013.01 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/16** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 239/50** (2013.01 - EP); **C07D 251/54** (2013.01 - EP KR); **C07D 401/14** (2013.01 - EP); **C07D 403/12** (2013.01 - EP); **C07D 405/14** (2013.01 - EP); **C07D 409/12** (2013.01 - EP); **C07D 413/04** (2013.01 - EP); **C07D 471/08** (2013.01 - EP); **C07D 487/04** (2013.01 - EP); **C07D 498/08** (2013.01 - EP); **C07D 519/00** (2013.01 - EP)

C-Set (source: EP)
1. **A61K 31/522 + A61K 2300/00**
2. **A61K 31/433 + A61K 2300/00**
3. **A61K 31/57 + A61K 2300/00**
4. **A61K 31/53 + A61K 2300/00**
5. **A61K 31/519 + A61K 2300/00**
6. **A61K 31/5355 + A61K 2300/00**
7. **A61K 31/505 + A61K 2300/00**

Citation (search report)

- [A] US 5661148 A 19970826 - SAKUMA YASUJI [JP], et al
- [XP] WO 2012074999 A1 20120607 - GALLEON PHARMACEUTICALS INC [US], et al
- [XP] US 2012295911 A1 20121122 - MANNION JAMES C [US], et al
- [E] WO 2014078575 A2 20140522 - GALLEON PHARMACEUTICALS INC [US]
- [A] HIDEKI HORIUCHI ET AL: "Beneficial effects of a novel anti-hypoxemic agent, TEI-7322, on bleomycin-induced experimental hypoxemia in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 287, no. 1, 1 December 1995 (1995-12-01), pages 27 - 34, XP055213185, ISSN: 0014-2999, DOI: 10.1016/0014-2999(95)00468-7
- See references of WO 2013181217A2

Cited by
FR3076751A1; WO2019141916A1

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2013181217 A2 20131205; WO 2013181217 A3 20140206; AU 2013267570 A1 20141218; BR 112014029703 A2 20170627; CA 2875012 A1 20131205; CN 104602694 A 20150506; EP 2855438 A2 20150408; EP 2855438 A4 20160224; HK 1209118 A1 20160324; JP 2015521201 A 20150727; KR 20150020616 A 20150226; SG 11201407964Y A 20141230

DOCDB simple family (application)
US 2013043052 W 20130529; AU 2013267570 A 20130529; BR 112014029703 A 20130529; CA 2875012 A 20130529; CN 201380040132 A 20130529; EP 13798039 A 20130529; HK 15109840 A 20151008; JP 2015515140 A 20130529; KR 20147036621 A 20130529; SG 11201407964Y A 20130529